How is psoriasis best managed in the primary care setting? Take this quick quiz to test your knowledge.
Here’s a brief look at medications for rheumatologic disorders that were approved or granted a new indication in 2018.
New recommendations from the National Psoriasis Foundation offer answers. The express goal of these guidelines: to reduce disease severity through proper nutrition.
Two recent studies focus on the risks of osteoporosis and cardiovascular disease in patients on the psoriatic arthritis/psoriasis spectrum.
A diagnostic challenge: foot and ankle tendinopathy or enthesopathy in patients with psoriasis who do not have psoriatic arthritis.
The approval makes Cimzia the first Fc-free, PEGylated anti-TNF treatment option for this indication.
Most patients seen in primary care have mild to moderate plaque psoriasis, which is usually treatable with topical therapies.
This novel interleukin-23 inhibitor targets psoriatic inflammation.
Help your patients help themselves. Take a look at 6 rheumatology apps you can discuss at the next visit.
In late-breaking clinical trials, 3 novel biologic drugs show promise for the treatment of moderate to severe plaque psoriasis.